Duty Stuart 4

What Happened
Duty Stuart, a member of Foghorn Therapeutics' board of directors, was granted a derivative award for 28,000 shares on 2026-06-24. The grant is recorded at an acquisition price of $4.08 per share, for a total recorded value of $114,240. This was a grant/award (not an open-market purchase or sale) and represents director compensation rather than a direct cash outlay or sale.

Key Details

• Transaction date: 2026-06-24; SEC filing date: 2026-06-25 (Accession: 0001970274-26-000007).
• Security: derivative award reported as 28,000 shares @ $4.08 = $114,240.
• Shares owned after transaction: not disclosed in this filing.
• Footnote: the option vests in full on the first anniversary of the grant date, subject to continued service on the board.
• Transaction type: A = Award/Grant (derivative). No 10b5-1 plan, tax withholding, or late-filing note included in the filing.

Context
This is a standard director equity award used for compensation and retention. Because the grant vests one year from the grant date, the shares are not immediately executable unless the director remains in service. Awards are routine and do not necessarily signal the insider’s view on the stock; they differ from outright purchases, which can be interpreted as a direct bullish signal.